| Literature DB >> 27854319 |
Lyudmila V Bel'skaya1,2, Victor K Kosenok3,4, Gilbert Massard5.
Abstract
This research was aimed at a search for regularities in changes to parameters of endogenous intoxication and saliva lipid peroxidation in patients with lung cancer, non-malignant lung diseases, and apparently healthy people. All patients went through saliva sampling at an amount of 1 mL. A concentration of malondialdehyde (MDA) was measured according to a reaction with thiobarbituric acid, and a level of middle molecules (MM) was measured with UV spectroscopy at 254 and 280 nm, while the content of lipid peroxidation products was measured according to a degree of heptane extract light absorption at wavelengths of 220, 232, 278, and 400 nm. It has been revealed that in the context of lung cancer, the level of diene conjugates decreases, increasing the level of triene conjugates, Schiff's bases, and MM. As a tumor grows, there is a decrease in the level of lipid peroxidation primary products and an increase in endotoxemia phenomena. The process is more apparent when going from local to locally advanced disease states. The nature of the MDA change is nonlinearly associated with tumor progression. The findings might be used to optimize traditional aids of diagnostics, in disease state forecasting, in treatment monitoring, etc.Entities:
Keywords: lipid peroxidation; lung cancer; malondialdehyde; middle molecules; saliva
Year: 2016 PMID: 27854319 PMCID: PMC5192514 DOI: 10.3390/diagnostics6040039
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
MM levels under normal conditions depending on gender and age.
| Age, Years | Gender | MM at 254 nm | MM at 280 nm | MM at 280/254 nm |
|---|---|---|---|---|
| 40–49 | M | 0.327 ± 0.024 | 0.265 ± 0.020 | 0.810 ± 0.021 |
| F | 0.310 ± 0.022 | 0.265 ± 0.025 | 0.855 ± 0.019 | |
| 50–59 | M | 0.364 ± 0.021 | 0.295 ± 0.024 | 0.810 ± 0.022 |
| F | 0.315 ± 0.018 | 0.264 ± 0.021 | 0.838 ± 0.021 | |
| 60–69 | M | 0.361 ± 0.022 | 0.325 ± 0.023 | 0.900 ± 0.019 |
| – | ||||
| F | 0.316 ± 0.020 | 0.261 ± 0.018 | 0.825 ± 0.024 | |
| Over 70 | M | 0.451 ± 0.021 | 0.417 ± 0.019 | 0.924 ± 0.018 |
| F | 0.361 ± 0.018 | 0.317 ± 0.023 | 0.878 ± 0.025 | |
| – |
Note: p—statistically significant differences compared to the age group of 40–49.
MM levels depending on gender and age in patients with lung cancer.
| Age, Years | Gender | MM at 254 nm | MM at 280 nm | MM at 280/254 nm |
|---|---|---|---|---|
| 40–49 | M | 0.240 ± 0.020 | 0.203 ± 0.017 | 0.935 ± 0.026 |
| F | 0.249 ± 0.019 | 0.212 ± 0.023 | 0.914 ± 0.026 | |
| 50–59 | M | 0.282 ± 0.022 | 0.257 ± 0.026 | 1.017 ± 0.022 |
| – | – | |||
| F | 0.275 ± 0.018 | 0.254 ± 0.024 | 0.995 ± 0.023 | |
| 60–69 | M | 0.314 ± 0.017 | 0.290 ± 0.023 | 1.010 ± 0.029 |
| F | 0.314 ± 0.020 | 0.284 ± 0.023 | 0.985 ± 0.021 | |
| Over 70 | M | 0.313 ± 0.019 | 0.301 ± 0.024 | 0.953 ± 0.018 |
| – | ||||
| F | 0.328 ± 0.021 | 0.292 ± 0.021 | 0.908 ± 0.022 | |
| – |
Note: p—statistically significant differences compared to the age group of 40–49.
Figure 1Dynamics of MM levels under normal conditions and in the context of cancer pathology.
Figure 2Levels of diene conjugates in saliva of patients with lung cancer, non-malignant lung diseases and of apparently healthy patients.
Levels of triene conjugates in saliva of patients with lung cancer, non-malignant lung diseases and of apparently healthy patients (control).
| Age, Years | Control (1) | Non-Malignant Lung Disease (2) | Lung Cancer (3) |
|---|---|---|---|
| 30–39 | 0.859 ± 0.014 | 1.033 ± 0.011 | 1.089 ± 0.021 |
| – | – | ||
| 40–49 | 0.885 ± 0.011 | 1.057 ± 0.016 | 1.084 ± 0.019 |
| – | |||
| 50–59 | 0.886 ± 0.015 | 1.058 ± 0.015 | 1.083 ± 0.014 |
| 60–69 | 0.899 ± 0.021 | 1.075 ± 0.015 | 1.088 ± 0.016 |
| Over 70 | 0.953 ± 0.015 | NA | 1.128 ± 0.009 |
| – |
Note: p1—statistically significant differences compared to the age group of 30–39; p2—statistically significant differences compared to the control group.
Levels of Shiff bases in saliva of patients with lung cancer, non-malignant lung diseases and of apparently healthy patients (control).
| Age, Years | Control (1) | Non-Malignant Lung Disease (2) | Lung Cancer (3) |
|---|---|---|---|
| 30–39 | 0.515 ± 0.014 | 0.584 ± 0.018 | 0.632 ± 0.017 |
| – | – | ||
| 40–49 | 0.529 ± 0.011 | 0.590 ± 0.017 | 0.631 ± 0.020 |
| – | – | ||
| 50–59 | 0.534 ± 0.016 | 0.621 ± 0.021 | 0.629 ± 0.015 |
| 60–69 | 0.557 ± 0.010 | 0.623 ± 0.017 | 0.625 ± 0.010 |
| Over 70 | 0.637 ± 0.020 | NA | 0.611 ± 0.010 |
| – | – |
Note: p1—statistically significant differences compared to the age group of 30–39; p2—statistically significant differences compared to the control group.
Figure 3State of lipid peroxidation processes depending on the disease stage.
Figure 4Dynamics of MDA levels depending on age.
Figure 5Dynamics of MDA level, depending on disease stage.